Versartis Stock Price, News & Analysis (NASDAQ:VSAR)

$1.82 -0.03 (-1.62 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$1.85
Today's Range$1.75 - $1.90
52-Week Range$1.60 - $24.00
Volume710,407 shs
Average Volume804,734 shs
Market Capitalization$62.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31

About Versartis (NASDAQ:VSAR)

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop somavaratan for additional growth disorders, such as idiopathic short stature (ISS), small for gestational age (SGA) and Turner Syndrome. Somavaratan is engineered using XTEN technology to extend the residence time in the bloodstream by reducing the clearance of recombinant human growth hormone (rhGH) from the body by the two primary mechanisms, kidney filtration and receptor mediated clearance.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:VSAR
  • CUSIP: N/A
  • Web: www.versartis.com
Debt:
  • Debt-to-Equity Ratio: 0.11%
  • Current Ratio: 1.52%
  • Quick Ratio: 1.52%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.38 per share
  • Price / Book: 1.32
Profitability:
  • Trailing EPS: ($3.93)
  • Net Income: ($95,810,000.00)
  • Return on Equity: -131.09%
  • Return on Assets: -79.18%
Misc:
  • Employees: 59
  • Outstanding Shares: 35,810,000
 

Frequently Asked Questions for Versartis (NASDAQ:VSAR)

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis, Inc. (NASDAQ:VSAR) issued its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.78. During the same quarter in the previous year, the business earned ($0.92) earnings per share. View Versartis' Earnings History.

Where is Versartis' stock going? Where will Versartis' stock price be in 2017?

10 equities research analysts have issued 1 year price objectives for Versartis' shares. Their forecasts range from $3.00 to $20.00. On average, they anticipate Versartis' share price to reach $7.22 in the next twelve months. View Analyst Ratings for Versartis.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:

  • Srinivas Akkaraju M.D. Ph.D., Independent Chairman of the Board (Age 49)
  • Jay P. Shepard, President, Chief Executive Officer, Independent Director (Age 59)
  • Joshua T. Brumm, Chief Financial Officer, Chief Operating Officer (Age 39)
  • Shane M. Ward, Senior Vice President, General Counsel (Age 42)
  • Jay P. Stout, Senior Vice President, Technical Operations (Age 55)
  • Robert Gut M.D., Ph.D., Chief Medical Officer
  • Paul Westberg, Chief Business Officer (Age 49)
  • Tracy M. Woody, Chief Commercial Officer (Age 46)
  • Eric L. Dobmeier, Director (Age 48)
  • R. Scott Greer, Independent Director (Age 58)

Who owns Versartis stock?

Versartis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (5.27%), JPMorgan Chase & Co. (2.55%), Artal Group S.A. (1.12%), Sphera Funds Management LTD. (0.92%), Jane Street Group LLC (0.36%) and First Quadrant L P CA (0.34%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm, Life Sciences Maste Perceptive, Paul Westberg, Perceptive Advisors Llc, Shahzad Malik, Shane Ward and Srinivas Akkaraju. View Institutional Ownership Trends for Versartis.

Who sold Versartis stock? Who is selling Versartis stock?

Versartis' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, JPMorgan Chase & Co. and Sphera Funds Management LTD.. Company insiders that have sold Versartis company stock in the last year include Colin Hislop, Edmon R Jennings, Jay Shepard, Joshua T Brumm, Life Sciences Maste Perceptive, Paul Westberg, Shahzad Malik and Shane Ward. View Insider Buying and Selling for Versartis.

Who bought Versartis stock? Who is buying Versartis stock?

Versartis' stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, First Quadrant L P CA, Orbimed Advisors LLC and Artal Group S.A.. Company insiders that have bought Versartis stock in the last two years include Perceptive Advisors Llc and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy Versartis stock?

Shares of Versartis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of Versartis stock can currently be purchased for approximately $1.82.

How big of a company is Versartis?

Versartis has a market capitalization of $62.67 million. The biopharmaceutical company earns ($95,810,000.00) in net income (profit) each year or ($3.93) on an earnings per share basis. Versartis employs 59 workers across the globe.

How can I contact Versartis?

Versartis' mailing address is 4200 Bohannon Drive Suite 250, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]


MarketBeat Community Rating for Versartis (NASDAQ VSAR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Versartis (NASDAQ:VSAR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 7 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: $7.22 (296.83% upside)

Consensus Price Target History for Versartis (NASDAQ:VSAR)

Price Target History for Versartis (NASDAQ:VSAR)

Analysts' Ratings History for Versartis (NASDAQ:VSAR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Cantor FitzgeraldSet Price TargetBuy$14.00N/AView Rating Details
9/25/2017Bank of America CorporationDowngradeBuy -> NeutralHighView Rating Details
9/25/2017Citigroup Inc.DowngradeBuy -> Neutral$23.00 -> $3.00HighView Rating Details
9/22/2017Canaccord GenuityReiterated RatingBuy$28.00 -> $9.00N/AView Rating Details
9/22/2017Morgan StanleyReiterated RatingEqual Weight$3.00 -> $4.00N/AView Rating Details
9/22/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$25.00 -> $4.00N/AView Rating Details
9/22/2017Cowen and CompanyDowngradeOutperform -> Market Perform$45.00 -> $3.00N/AView Rating Details
9/22/2017Barclays PLCDowngradeOverweight -> Equal Weight$28.00 -> $4.00N/AView Rating Details
9/22/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$26.00 -> $4.00N/AView Rating Details
12/20/2016Credit Suisse GroupUpgradeNeutral -> Outperform$11.00 -> $20.00N/AView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History and Estimates Chart for Versartis (NASDAQ:VSAR)

Earnings by Quarter for Versartis (NASDAQ:VSAR)

Earnings History by Quarter for Versartis (NASDAQ VSAR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017Q3 2017($0.62)($1.40)ViewN/AView Earnings Details
7/27/2017Q2 2017($0.84)($1.04)ViewN/AView Earnings Details
4/27/2017Q1 2017($0.71)($0.85)ViewN/AView Earnings Details
2/21/2017Q4 2016($0.62)($0.64)$10.00 millionViewN/AView Earnings Details
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Versartis (NASDAQ:VSAR)
2017 EPS Consensus Estimate: ($2.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.79)($0.79)($0.79)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.81)($0.81)($0.81)
Q4 20171($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Versartis (NASDAQ:VSAR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Versartis (NASDAQ VSAR)

Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 73.18%
Insider Trades by Quarter for Versartis (NASDAQ:VSAR)
Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Insider Trades by Quarter for Versartis (NASDAQ VSAR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2017Colin HislopInsiderSell667$2.55$1,700.85View SEC Filing  
10/19/2017Joshua T BrummCFOSell1,326$2.55$3,381.30View SEC Filing  
10/19/2017Shane WardSVPSell776$2.55$1,978.80View SEC Filing  
9/22/2017Life Sciences Maste PerceptiveMajor ShareholderSell2,130,000$3.29$7,007,700.00View SEC Filing  
6/13/2017Joshua T BrummCFOSell1,421$16.05$22,807.05View SEC Filing  
6/13/2017Paul WestbergSVPSell711$16.05$11,411.55View SEC Filing  
5/16/2017Joshua T. BrummCFOSell1,263$17.40$21,976.20View SEC Filing  
4/19/2017Paul WestbergSVPSell1,316$19.85$26,122.60View SEC Filing  
4/4/2017Colin HislopInsiderSell35,000$21.20$742,000.00View SEC Filing  
3/24/2017Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
3/17/2017Shahzad MalikDirectorSell483,670$18.11$8,759,263.70View SEC Filing  
3/15/2017Shahzad MalikDirectorSell166,330$19.09$3,175,239.70View SEC Filing  
3/15/2017Shane WardSVPSell2,041$19.01$38,799.41View SEC Filing  
2/27/2017Jay ShepardInsiderSell5,166$24.00$123,984.00View SEC Filing  
2/27/2017Paul WestbergSVPSell12,500$22.50$281,250.00View SEC Filing  
2/23/2017Jay ShepardInsiderSell16,000$19.25$308,000.00View SEC Filing  
2/23/2017Paul WestbergSVPSell25,000$18.75$468,750.00View SEC Filing  
2/13/2017Perceptive Advisors LlcMajor ShareholderBuy94,016$15.30$1,438,444.80View SEC Filing  
2/9/2017Perceptive Advisors LlcMajor ShareholderBuy145,823$13.72$2,000,691.56View SEC Filing  
2/3/2017Jay ShepardInsiderSell6,719$13.69$91,983.11View SEC Filing  
2/2/2017Jay ShepardInsiderSell24,211$13.77$333,385.47View SEC Filing  
1/30/2017Jay ShepardInsiderSell17,270$13.52$233,490.40View SEC Filing  
1/30/2017Joshua T BrummCFOSell2,945$13.85$40,788.25View SEC Filing  
1/30/2017Paul WestbergSVPSell1,916$13.85$26,536.60View SEC Filing  
1/11/2017Paul WestbergVPSell7,931$15.24$120,868.44View SEC Filing  
1/10/2017Paul WestbergVPSell11,213$15.66$175,595.58View SEC Filing  
1/9/2017Paul WestbergVPSell13,356$15.93$212,761.08View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$14.66$1,389,035.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy47,375$14.37$680,778.75View SEC Filing  
12/27/2016Joshua T BrummCFOSell990$15.85$15,691.50View SEC Filing  
12/27/2016Paul WestbergVPSell361$15.85$5,721.85View SEC Filing  
12/16/2016Paul WestbergVPSell5,000$15.00$75,000.00View SEC Filing  
12/8/2016Edmon R JenningsDirectorSell1,500$12.96$19,440.00View SEC Filing  
12/7/2016Joshua T BrummCFOSell3,021$13.25$40,028.25View SEC Filing  
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.00View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.24View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.75View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.55View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.40View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.60View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.28View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.00View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.00View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Versartis (NASDAQ:VSAR)

Latest Headlines for Versartis (NASDAQ VSAR)

Source:
DateHeadline
Versartis, Inc. (VSAR) Expected to Announce Earnings of -$0.98 Per ShareVersartis, Inc. (VSAR) Expected to Announce Earnings of -$0.98 Per Share
www.americanbankingnews.com - November 7 at 5:32 AM
Cantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price TargetCantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price Target
www.americanbankingnews.com - October 28 at 11:10 AM
Versartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic TransactionsVersartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic Transactions
www.streetinsider.com - October 28 at 8:25 AM
Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateVersartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - October 28 at 8:25 AM
Versartis Hires Cowen to Assist in Evaluating Potential Strategic TransactionsVersartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions
finance.yahoo.com - October 28 at 8:25 AM
Versartis, Inc. (VSAR) Posts Quarterly  Earnings Results, Misses Expectations By $0.78 EPSVersartis, Inc. (VSAR) Posts Quarterly Earnings Results, Misses Expectations By $0.78 EPS
www.americanbankingnews.com - October 27 at 3:40 PM
Head to Head Review: Versartis (VSAR) versus AcelRx Pharmaceuticals (ACRX)Head to Head Review: Versartis (VSAR) versus AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - October 27 at 3:06 AM
Versartis, Inc. (VSAR) Given Average Rating of "Hold" by AnalystsVersartis, Inc. (VSAR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 25 at 7:34 AM
Versartis, Inc. (VSAR) Set to Announce Quarterly Earnings on WednesdayVersartis, Inc. (VSAR) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Zacks: Analysts Anticipate Versartis, Inc. (VSAR) to Announce -$0.68 Earnings Per ShareZacks: Analysts Anticipate Versartis, Inc. (VSAR) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - October 18 at 12:28 PM
Versartis, Inc. (VSAR) Sees Large Increase in Short InterestVersartis, Inc. (VSAR) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 13 at 1:58 AM
Versartis, Inc. (VSAR) Receives Consensus Recommendation of "Hold" from BrokeragesVersartis, Inc. (VSAR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 30 at 6:44 AM
Versartis, Inc. (VSAR) Expected to Announce Earnings of -$0.68 Per ShareVersartis, Inc. (VSAR) Expected to Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - September 29 at 6:22 PM
FY2017 Earnings Estimate for Versartis, Inc. (VSAR) Issued By Cantor FitzgeraldFY2017 Earnings Estimate for Versartis, Inc. (VSAR) Issued By Cantor Fitzgerald
www.americanbankingnews.com - September 28 at 7:52 AM
Insider Selling: Versartis, Inc. (VSAR) Major Shareholder Sells 2,130,000 Shares of StockInsider Selling: Versartis, Inc. (VSAR) Major Shareholder Sells 2,130,000 Shares of Stock
www.americanbankingnews.com - September 25 at 7:14 PM
Bank of America Corporation Downgrades Versartis, Inc. (VSAR) to NeutralBank of America Corporation Downgrades Versartis, Inc. (VSAR) to Neutral
www.americanbankingnews.com - September 25 at 12:52 PM
Is Versartis Inc (VSAR) Undervalued?Is Versartis Inc (VSAR) Undervalued?
finance.yahoo.com - September 23 at 10:53 AM
Human Growth Drug Flop Sends This Biotech Crashing 83%Human Growth Drug Flop Sends This Biotech Crashing 83%
finance.yahoo.com - September 23 at 10:53 AM
Ascendis Pharma shares surge 42% on competitors flopAscendis Pharma shares surge 42% on competitor's flop
finance.yahoo.com - September 23 at 10:53 AM
Versartis Inc. (VSAR) Is Plummeting After Phase 3 Study FailedVersartis Inc. (VSAR) Is Plummeting After Phase 3 Study Failed
www.rttnews.com - September 23 at 10:53 AM
Versartis shares down 82%Versartis shares down 82%
www.marketwatch.com - September 23 at 10:53 AM
Versartis, Inc. (VSAR) PT Lowered to $9.00 at Canaccord GenuityVersartis, Inc. (VSAR) PT Lowered to $9.00 at Canaccord Genuity
www.americanbankingnews.com - September 22 at 3:14 PM
Versartis, Inc. (VSAR) Downgraded to Neutral at Piper Jaffray CompaniesVersartis, Inc. (VSAR) Downgraded to Neutral at Piper Jaffray Companies
www.americanbankingnews.com - September 22 at 12:40 PM
Versartis, Inc. (VSAR) Lowered to Underweight at Barclays PLCVersartis, Inc. (VSAR) Lowered to Underweight at Barclays PLC
www.americanbankingnews.com - September 22 at 12:40 PM
Cowen and Company Downgrades Versartis, Inc. (VSAR) to Market PerformCowen and Company Downgrades Versartis, Inc. (VSAR) to Market Perform
www.americanbankingnews.com - September 22 at 11:58 AM
Versartis, Inc. (VSAR) Stock Rating Lowered by SunTrust Banks, Inc.Versartis, Inc. (VSAR) Stock Rating Lowered by SunTrust Banks, Inc.
www.americanbankingnews.com - September 22 at 9:18 AM
Versartis, Inc. (VSAR) Earns "Equal Weight" Rating from Morgan StanleyVersartis, Inc. (VSAR) Earns "Equal Weight" Rating from Morgan Stanley
www.americanbankingnews.com - September 22 at 9:18 AM
Versartis, Inc. (VSAR) PT Lowered to $14.00Versartis, Inc. (VSAR) PT Lowered to $14.00
www.americanbankingnews.com - September 22 at 9:18 AM
Notable Thursday Option Activity: VMC, LGIH, VSARNotable Thursday Option Activity: VMC, LGIH, VSAR
www.thestreet.com - September 15 at 11:15 AM
Financial Contrast: Versartis (VSAR) versus its PeersFinancial Contrast: Versartis (VSAR) versus its Peers
www.americanbankingnews.com - September 11 at 1:06 PM
Versartis, Inc. (VSAR) Rating Reiterated by Piper Jaffray CompaniesVersartis, Inc. (VSAR) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - September 8 at 6:44 PM
Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017
finance.yahoo.com - September 8 at 10:07 AM
Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory AffairsVersartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs
finance.yahoo.com - September 6 at 10:04 AM
Versartis, Inc. (VSAR) Given Consensus Recommendation of "Buy" by BrokeragesVersartis, Inc. (VSAR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 6:28 AM
Implied Volatility Surging for Versartis (VSAR) Stock OptionsImplied Volatility Surging for Versartis (VSAR) Stock Options
finance.yahoo.com - September 1 at 10:54 AM
Cantor Fitzgerald Weighs in on Versartis, Inc.s FY2017 Earnings (VSAR)Cantor Fitzgerald Weighs in on Versartis, Inc.'s FY2017 Earnings (VSAR)
www.americanbankingnews.com - August 28 at 2:02 AM
Biotech Forum Daily Digest: An Update On Versartis Before Key Trial DataBiotech Forum Daily Digest: An Update On Versartis Before Key Trial Data
seekingalpha.com - August 23 at 11:44 PM
Cowen and Company Reiterates "Outperform" Rating for Versartis, Inc. (VSAR)Cowen and Company Reiterates "Outperform" Rating for Versartis, Inc. (VSAR)
www.americanbankingnews.com - August 23 at 1:10 PM
Versartis, Inc. (VSAR) Expected to Post Earnings of -$0.68 Per ShareVersartis, Inc. (VSAR) Expected to Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - August 23 at 8:12 AM
Versartis, Inc. (NASDAQ:VSAR) Receives Consensus Recommendation of "Buy" from BrokeragesVersartis, Inc. (NASDAQ:VSAR) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 11 at 3:24 PM
 Brokerages Expect Versartis, Inc. (VSAR) Will Post Earnings of -$0.68 Per Share Brokerages Expect Versartis, Inc. (VSAR) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - August 5 at 7:08 AM
Options Traders Expect Huge Moves in Versartis (VSAR) StockOptions Traders Expect Huge Moves in Versartis (VSAR) Stock
finance.yahoo.com - August 4 at 9:48 AM
Versartis to Present at the Canaccord Genuity Growth ConferenceVersartis to Present at the Canaccord Genuity Growth Conference
finance.yahoo.com - August 2 at 8:33 AM
Brokers Offer Predictions for Versartis, Inc.s FY2021 Earnings (NASDAQ:VSAR)Brokers Offer Predictions for Versartis, Inc.'s FY2021 Earnings (NASDAQ:VSAR)
www.americanbankingnews.com - July 31 at 10:36 AM
Versartis, Inc. (VSAR) Posts  Earnings Results, Misses Expectations By $0.20 EPSVersartis, Inc. (VSAR) Posts Earnings Results, Misses Expectations By $0.20 EPS
www.americanbankingnews.com - July 28 at 4:28 PM
Canaccord Genuity Analysts Give Versartis, Inc. (VSAR) a $28.00 Price TargetCanaccord Genuity Analysts Give Versartis, Inc. (VSAR) a $28.00 Price Target
www.americanbankingnews.com - July 28 at 2:08 PM
Versartis Reports Second Quarter 2017 Financial ResultsVersartis Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 28 at 9:46 AM
Versartis reports 2Q lossVersartis reports 2Q loss
finance.yahoo.com - July 28 at 9:46 AM
Versartis, Inc. (VSAR) Given a $34.00 Price Target at Cantor FitzgeraldVersartis, Inc. (VSAR) Given a $34.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - July 27 at 6:43 PM
Versartis, Inc. (VSAR) to Release Quarterly Earnings on WednesdayVersartis, Inc. (VSAR) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:15 AM

Social Media

Financials

Chart

Versartis (NASDAQ VSAR) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.